Impact of Exacerbations in Type 2 Inflammatory Respiratory Diseases

During the Delta wave of COVID-19, higher caseload strain negatively impacted patient survival rates across US hospitals, regardless of their size or resources.

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

Donor lymphocyte infusion, both alone and in combination with azacitidine, restored CD34 levels in two-thirds of patients with a baseline CD34 donor chimerism of less than 80%.

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

Siow Ming Lee, PhD, FRCP, University College London Hospitals, discusses essential advancements necessary for improving immunotherapy outcomes in special patient subgroups with lung cancer.

The therapeutic landscape for non–small cell lung cancer (NSCLC) has been relatively stable since the 2016 approval of pembrolizumab, but results presented at the 2024 World Conference on Lung Cancer could shake up that status quo.